Chronic Lymphocytic Leukemia (CLL) with Eugen Tausch

In this episode of HealthTalk TV, we take a deep dive into the rapidly evolving treatment landscape of chronic lymphocytic leukemia (CLL). Host Lars Brock Nilsen is joined by Dr. Eugen Tausch, a leading international expert in CLL at the University Hospital in Ulm, to discuss how the field is moving away from chemotherapy and toward targeted, fixed-duration therapies — and what this means for patients in clinical practice.Together, they explore the key questions shaping CLL treatment today: how do you choose between continuous BTK inhibitor therapy and time-limited venetoclax-based combinations? What role should patient preferences play? And what does the latest clinical trial data tell us about the best strategy for different patient profiles?Topics covered in this episode:• What is CLL, and why is its course so heterogeneous?• The shift from chemoimmunotherapy to targeted therapies• BTK inhibitors vs. venetoclax-based combinations: how to choose• The importance of genetic risk factors (IGHV, TP53, del17p)• Patient involvement and shared decision-making• Key findings from the CLL17 trial• Treatment sequencing and managing relapse• Non-covalent BTK inhibitors and Pirtobrutinib: promise and open questions• What's on the horizon: BTK degraders, bispecifics, and CAR-T in CLLDr. Tausch offers a nuanced and clinically grounded perspective on a field that continues to evolve at remarkable speed — and shares why he believes the best strategies are still being defined.Explore more from HealthTalk:– Read our news coverage: www.healthtalk.no– Sign up for our newsletter: https://www.healthtalk.no/signup– Watch more interviews and broadcasts on YouTube– Follow us on LinkedIn for analyses aimed at the healthcare community Hosted on Acast. See acast.com/privacy for more information.